Health
FDA Authorizes Marketing of Device to Improve Gait in Multiple Sclerosis Patients – FDA.gov
FDA has authorized marketing of a new device intended for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis
For Immediate Release:
March 26, 2021
Today, the U.S. Food and Drug Administration authorized marketing of a new device indicated for use as a short-term treatment of gait deficit due to mild to moderate symptoms from multiple sclerosis (MS). The device is intended to be used by prescription only as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and older. The device, called Portable Neuromodulation Stimulator (PoNS), is a neuromuscular tongue stimulator that…
-
General11 hours agoPolice investigating after body found on road in Newborough, Gippsland
-
Noosa News23 hours agoDeaths of Karen Edwards, Tim Thomson, and Gordon Twaddle re-examined in inquest
-
Noosa News24 hours agoSecond inquest into homicide of three tourists shot dead Mount Isa in 1978 begins
-
General24 hours agoThe Church of England’s ‘turning point’ to irrelevancy